Background The intractability of castration-resistant prostate cancer (CRPC) is exacerbated
by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis …

Simple Summary Prostate cancer is the second most common cancer in males. In prostate
cancer cells, androgens bind and activate the intracellular mediator called Androgen …

BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with
diverse drivers of disease progression and mechanisms of therapeutic resistance. We …

Castration-resistant prostate cancer (CRPC) remains an incurable and lethal malignancy.
The development of new CRPC treatment strategies is strongly impeded by the scarcity of …

The androgen receptor (AR) is the main therapeutic target in advanced prostate cancer,
because it regulates the growth and progression of prostate cancer cells. Patients may …

Resistance to second-generation androgen receptor (AR) antagonists such as enzalutamide
is an inevitable consequence in patients with castration-resistant prostate cancer (CRPC) …

Abstract Treatment options for metastatic castration-resistant prostate cancer (CRPC) have
evolved with the established benefit of the novel androgen receptor (AR)-targeted agents …

Current treatments for castration resistant prostate cancer (CRPC) largely fall into two
classes: androgen receptor (AR)-targeted therapies such as the next-generation …

Context Androgen deprivation therapy (ADT) is the backbone of treatment for advanced
prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably …